VDM11

VDM11 is a **selective anandamide membrane transporter inhibitor** that blocks the reuptake of anandamide, an endogenous cannabinoid ligand. By inhibiting the anandamide transporter (AMT), VDM11 elevates anandamide levels with minimal effects on other endocannabinoids like 2-AG. The compound has been investigated for its **antitussive effects** (cough suppression), where it acts through peripheral CB1 cannabinoid receptor activation. VDM11 has also been studied in **nicotine addiction research**, showing efficacy in attenuating reinstatement of nicotine-seeking behavior induced by cues or nicotine priming. Additionally, VDM11 may function as a substrate for fatty acid amide hydrolase (FAAH), potentially inhibiting the enzymatic degradation of anandamide and related compounds. The antitussive mechanism involves preventing substance P release from capsaicin-sensitive sensory nerve fibers. The compound has been **withdrawn from commercial sale** but was previously studied in preclinical research for pain, motor impairments, anxiety, and addiction-related behaviors.

Other names

N-arachidonoyl-(2-methyl-4-hydroxyphenyl) amine